China Drug Makers Move To R&D Ties With MNCs Such As Pfizer, Bristol
This article was originally published in PharmAsia News
Chinese drug makers are seeking a change in specialties that multinational pharmaceutical companies target when they seek local collaborations, from one on sales tie-ups to research and development.
You may also be interested in...
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.